Abcam to license in VHH phage library(1) from Twist, complementing in-house recombinant antibody capabilities
Abcam to develop and commercialize antibodies for diagnostic and research use, with Twist retaining rights for therapeutic applications
Reinforces Abcam’s commitment to consistently improve industry standards and support the sector with best-in-class reagents
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.